Trends and perspectives in the HIV vaccine research over the past thirty-five years: a scientometrics analysis through CiteSpace.
Saved in:
| Title: | Trends and perspectives in the HIV vaccine research over the past thirty-five years: a scientometrics analysis through CiteSpace. |
|---|---|
| Authors: | Chen, Xuannan1 (AUTHOR), Zhuo, Yizhou1 (AUTHOR), Lai, Yu2 (AUTHOR) yulai06@cdutcm.edu.cn |
| Source: | AIDS Reviews. Oct-Dec2025, Vol. 27 Issue 4, p138-152. 15p. |
| Subjects: | AIDS vaccines, IMMUNE response, ANTIGEN-antibody reactions, DATA visualization, ANTIBODY diversity, NATIONAL Institutes of Health (U.S.), ANTIRETROVIRAL agents, SCIENTOMETRICS |
| Geographic Terms: | UNITED States |
| Abstract: | Despite advances in antiretroviral therapy, developing an effective human immunodeficiency virus (HIV) vaccine remains pivotal for epidemic control. Through a scientometric analysis of 19,863 publications from the Web of Science Core Collection (1989-2023) using CiteSpace, this study delineates evolving trends and emerging frontiers in HIV vaccine research. The United States dominated contributions, with institutions like the National Institutes of Health and Harvard leading productivity. Clustering revealed two interconnected research trajectories, which are broad neutralizing antibody development, broad neutralizing antibody precursors, and immune mechanism exploration. Despite efficacy trials not resulting in licensed HIV vaccine advancements in antigen design and adjuvant strategies, they show promise. Key findings indicated structural biology, germinal center (GC) dynamics, antibody-dependent cellular cytotoxicity, and glycosylation shielding as pivotal research domains. Critical barriers include generating a specific immune response to new epitopes and glycosylation-mediated immune evasion. Future efforts should prioritize GC optimization to enhance B-cell affinity maturation, structure-guided epitope targeting through cryo-electron microscopy, and advances in antigen delivery. In addition, engineering vaccines to expand CXCR5+ T follicular helper cell populations may improve durable humoral immunity. This analysis underscores the necessity of multidisciplinary approaches to overcome HIV vaccine hurdles. [ABSTRACT FROM AUTHOR] |
| Copyright of AIDS Reviews is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Despite advances in antiretroviral therapy, developing an effective human immunodeficiency virus (HIV) vaccine remains pivotal for epidemic control. Through a scientometric analysis of 19,863 publications from the Web of Science Core Collection (1989-2023) using CiteSpace, this study delineates evolving trends and emerging frontiers in HIV vaccine research. The United States dominated contributions, with institutions like the National Institutes of Health and Harvard leading productivity. Clustering revealed two interconnected research trajectories, which are broad neutralizing antibody development, broad neutralizing antibody precursors, and immune mechanism exploration. Despite efficacy trials not resulting in licensed HIV vaccine advancements in antigen design and adjuvant strategies, they show promise. Key findings indicated structural biology, germinal center (GC) dynamics, antibody-dependent cellular cytotoxicity, and glycosylation shielding as pivotal research domains. Critical barriers include generating a specific immune response to new epitopes and glycosylation-mediated immune evasion. Future efforts should prioritize GC optimization to enhance B-cell affinity maturation, structure-guided epitope targeting through cryo-electron microscopy, and advances in antigen delivery. In addition, engineering vaccines to expand CXCR5+ T follicular helper cell populations may improve durable humoral immunity. This analysis underscores the necessity of multidisciplinary approaches to overcome HIV vaccine hurdles. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 11396121 |
| DOI: | 10.24875/AIDSRev.25000018 |
